Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jan 22, 2026
Reporting period
Not applicable
Filed with the SEC
Jan 26, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0000875320-26-000022
Filed / recorded
Jan 26, 2026, 9:30 PM UTC
Added to OQRO
Oct 2, 2026, 12:29 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
VERTEX PHARMACEUTICALS INC / MA
Issuer CIK
875320
Ticker
VRTX
Reporting person
Duncan Mckechnie
Relationship
Officer
Officer title
EVP, Chief Commercial Officer
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Jan 22, 2026
Transaction code
A
Shares / units
2,080
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
22,938
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026.